2009•PubMedRequires access

[Hormones and osteoporosis update. FGF23/Klotho and bone metabolism].

Seiji Fukumoto

Abstract

Fibroblast growth factor (FGF) 23 is a hormone which is produced by bone and lowers serum phosphate and 1,25-dihydroxyvitamin D levels by acting on kidney. FGF23 works through binding to Klotho-FGF receptor complex. Because excess and deficient actions of FGF23 result in metabolic bone diseases, FGF23/Klotho pathway is physiologically important for maintaining normal bone metabolism.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Klotho, Fibroblast growth factor 23, Bone remodeling, Fibroblast growth factor, Endocrinology, Internal medicine, Osteoporosis, Hormone